Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China

25 May 2023
www.pharmaceutical-technology.com
AcquisitionDrug ApprovalVaccine
Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China
Preview
Source: Pharmaceutical Technology
Clover Biopharmaceuticals will benefit from the extensive sales and distribution network of Kyuan Trade. Credit: Clover Biopharmaceuticals.
Clover Biopharmaceuticals has established a commercial collaboration with Keyuan Xinhai (Beijing) Medical Products Trading (Kyuan Trade) for the launch of its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), in China.
The China National Medical Products Administration approved AdimFlu-S (QIS) in January 2022 for individuals aged three years and above.
Recommended Reports
Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China
Preview
Source: Pharmaceutical Technology
ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData
Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China
Preview
Source: Pharmaceutical Technology
ReportsGlobal Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research GlobalData
View all
The vaccine contains haemagglutinin from four influenza virus strains, two A and two B.
This increases the vaccine’s chance of high effectiveness against seasonal influenza compared to trivalent options.
Clover Biopharmaceuticals will use Kyuan Trade’s extensive sales and distribution network to complement its in-house capabilities and increase access to its AdimFlu-S (QIS) across the country.
Clover Biopharmaceuticals CEO and executive director Joshua Liang stated: “We are thrilled to partner with Kyuan Trade, which has a large and talented commercial team, a broad distribution network that extends across 31 provinces, municipalities and autonomous regions, and an excellent modern logistics network.
“With the seasonal influenza market in China poised for continued growth, this partnership is expected to help accelerate our commercial success and near-term revenue potential.”
The Chinese market for the seasonal influenza vaccine has been growing by 30% per year.
Clover Biopharmaceuticals expects to launch the influenza vaccine in the second half of 2023.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.